Placental membrane may speed burn healing in new clinical trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * One or more thermal burns classified as either superficial partial thickness or deep partial thickness. * Total Body Surface Area (TBSA) involvement between 5% and 15%. * Total burn index wound area is greater than 25 cm 2 and less than 0.25 m 2 (2500 cm 2 ) * 1 If 2 or more burns are present, each must have an area greater than 15 cm 2 * The participant must be willing and able to participate in the informed consent process. Exclusion Criteria: * Full thickness burns. * Burns present for \>72 hours prior to study evaluation * Burns requiring immediate autografting. * Superficial burns (1 st -degree) or burns not meeting criteria to be included in TBSA calculations. * Chemical or electrical burns. * Burns secondary to blast injury. * Burns causing vascular or respiratory compromise and burns requiring escharotomy * Any severe systemic comorbidities which could impair healing (e.g. active sepsis or major organ failure). * Known coagulopathy, platelet disorder, INR \> 1.6, PTT \> 38s, or platelets \< 50,000 per mm 3 * Uncontrolled diabetes. * Known life expectancy of \< 6 months. * Evidence of active infection in burn. * Target area for treatment includes the head, neck, palms of hands, soles of the feet, or genitals. * Viral infection which could impair healing or immune function (e.g. HIV, HBV, HCV) * Participants of childbearing potential who are pregnant, considering becoming pregnant within the next 6 months, and/or are unwilling to utilize an appropriate form of contraception. * Currently requiring dialysis or planning to start within 6 months. * Medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments. * Treated with hyperbaric oxygen therapy or a skin substitute within the 30 days prior to screening visit. * Sensitivity to ofloxacin, vancomycin, or amphotericin antibiotics. * Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.